John's Story
Cancer couldn’t conquer Jonathan Yaryan’s fighting spirit. The 77-year-old Vietnam veteran spent 30 years as an Air Force pilot, before retiring to Missouri City, Texas, in 2004 with his wife, Jeri. “I’ve had many close calls in my flying career, and I’ve looked at the grim reaper many times,” says Yaryan.
Retirement, however, did not go as planned: In 2011, Yaryan found himself battling for his life, once again, when he was diagnosed with stage IV prostate cancer. Under the care of Dr. Ana Aparicio and Dr. Padmanee Sharma of The University of Texas MD Anderson Cancer Center, Yaryan enrolled in a phase II clinical trial to test the immunotherapy ipilimumab (Yervoy™) in combination with the hormone therapy leuprolide (Lupron®). Ipilimumab—a drug developed by CRI’s Scientific Advisory Council director James P. Allison, Ph.D.—works by enhancing the ability of immune cells to destroy cancer cells.
Two years after beginning the clinical trial, Yaryan’s cancer is no longer holding him back. He spends his days babysitting his large brood of grandchildren, spending time with his wife, and taking long walks with his dog, Lucky. He is also a vocal advocate for clinical trials, particularly for late-stage cancer patients: “A lot of people are really hesitant to do these clinical trials, but if it’s offered, I encourage anybody to take advantage of it,” says Yaryan. “My cancer has now become a chronic disease and is well under control. I believe Lupron and the ipilimumab trial were critical.”
UPDATE: John passed away at age 82 on July 9, 2018. This profile was originally published May 6, 2013.